WINT vs. CMND, SNGX, ONVO, ABVC, ALZN, FRTX, MAAQ, CANF, ELAB, and SPRC
Should you be buying Windtree Therapeutics stock or one of its competitors? The main competitors of Windtree Therapeutics include Clearmind Medicine (CMND), Soligenix (SNGX), Organovo (ONVO), ABVC BioPharma (ABVC), Alzamend Neuro (ALZN), Fresh Tracks Therapeutics (FRTX), Mana Capital Acquisition (MAAQ), Can-Fite BioPharma (CANF), Elevai Labs (ELAB), and SciSparc (SPRC). These companies are all part of the "pharmaceutical products" industry.
Windtree Therapeutics vs.
Clearmind Medicine (NASDAQ:CMND) and Windtree Therapeutics (NASDAQ:WINT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.
Windtree Therapeutics received 3 more outperform votes than Clearmind Medicine when rated by MarketBeat users.
Windtree Therapeutics has a consensus price target of $350.00, suggesting a potential upside of 7,945.98%. Given Windtree Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Windtree Therapeutics is more favorable than Clearmind Medicine.
96.1% of Clearmind Medicine shares are held by institutional investors. Comparatively, 29.3% of Windtree Therapeutics shares are held by institutional investors. 0.3% of Windtree Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Clearmind Medicine is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.
Clearmind Medicine's return on equity of -129.21% beat Windtree Therapeutics' return on equity.
In the previous week, Windtree Therapeutics had 6 more articles in the media than Clearmind Medicine. MarketBeat recorded 6 mentions for Windtree Therapeutics and 0 mentions for Clearmind Medicine. Clearmind Medicine's average media sentiment score of 0.00 beat Windtree Therapeutics' score of -0.09 indicating that Clearmind Medicine is being referred to more favorably in the media.
Clearmind Medicine has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Windtree Therapeutics has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.
Summary
Clearmind Medicine beats Windtree Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Windtree Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Windtree Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:WINT) was last updated on 2/22/2025 by MarketBeat.com Staff
Free WINT Stock Alerts